- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00412321
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
June 30, 2014 updated by: Centocor, Inc.
A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This research study will use a type of drug called anti-IL-6 antibody, also known as CNTO 328.
An antibody is a substance in the body that fights infection.
CNTO 328 is an investigational drug that has been shown to slow down tumor growth or shrink tumors when tested in animals.
In a previous clinical trial in patients with multiple myeloma (blood cancer), CNTO 328 appeared to be a potent inhibitor of IL-6 .
One study has been completed for kidney cancer.
There are studies ongoing in humans with multiple myeloma and prostate cancer to see if CNTO 328 is safe and to see what effects it has on these types of cancer.
This is an open-label, nonrandomized, dose-finding phase 1 study with CNTO 328 in patients with B- cell non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's disease.
The purpose of this study is to evaluate different doses and schedules of CNTO 328 to see which dose/schedule is safe.
CNTO 328 will be given through a small tube that goes directly into your vein, called an intravenous (IV) infusion.
Depending on when the patient enters the study, the patient will be assigned to receive one course of CNTO 328 in one of the following groups: Group 1: 3 mg/kg 2 hr IV infusion every 2 weeks for 4 doses.
Group 2: 6 mg/kg 2 hr IV infusion every 2 weeks for 4 doses.
Group 3: 12 mg/kg 2 hr IV infusion every 3 weeks for 3 doses.
Group 4: 6 mg/kg 2 hr IV infusion every week for 7 doses.
Group 5: 12 mg/kg 2 hr IV infusion every 2 weeks for 4 doses.
Group 6: 12 mg/kg 1 hr IV infusion every 3 weeks for 3 doses.
Group 7a: 9 mg/kg 1 hr IV infusion every 3 weeks.
Group 7b: 12 mg/kg 1hr IV infusion every 3 weeks for Castleman's patients only.
In Groups 1-5, the overall amount of study drug that will be given increases with each higher group.
Group 1 will be filled before Group 2 starts and Group 2 will be filled before Group 3 starts, etc.
In this way, CNTO 328 can be tested more safely.
Both the patient and the study doctor will know to which group the patient is assigned.
Patients will remain in the group that they are assigned to for the entire time of participation in the study.
Up to 70 patients may take part in this study.
Patients in Groups 1-6 will be in the study for up to 34 weeks prior to Post Study Follow-Up.
Screening: up to 4 weeks before the first dose schedule of CNTO 328.
Treatment: up to 6 weeks of treatment with CNTO 328.
Extended Dosing: Patients assigned to Groups 1-6, and their cancer or disease has become stable or better while receiving CNTO 328, may be able to receive additional courses of study drug.
Patients in Group 7 will be in the study until their disease gets worse, they can no longer tolerate CNTO 328, the study doctor feels it is in their best interest to stop CNTO 328 or they longer wish to participate in the study.
Long Term Follow-Up: Patients will be contacted by telephone every six months after the last infusion of study drug to assess the patient's disease status and survival.
Dose (6-12 mg/kg) and frequency (weekly or 2 or 3 week intervals) of dosing depends upon Group assignment.
CNTO 328 will be given through a small tube that goes directly into your vein, called an intravenous (IV) infusion.
The infusion will take about 2 hours to complete for groups 1-5 and 1 hour for Groups 6 and 7.
In Groups 1-6, CNTO 328 will be given once every 1, 2 or 3 weeks from days 1 to 43 depending on treatment assignment.
In Group 7a and Group 7b, CNTO 328 will be given on day 1 of each 21 day cycle.
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
Florida
-
Tampa, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
New York
-
Box 302, New York, United States
-
New York, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's Disease which has progressed on or after standard therapy or for which there is no effective standard therapy, or which is not suitable for standard therapy
- Detectable serum C-Reactive Protein
- At least 4 weeks since prior systemic therapy, radiotherapy, or surgery
- Must meet protocol lab criteria (adequate bone marrow, liver and renal function) to be assessed at patient's first visit to the study center
Exclusion Criteria:
- Received any investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longer
- History of receiving murine or human-murine recombination products, such as G250, BE-8, and other monoclonal antibodies. (Note: Prior rituximab treatment is not an exclusion criterion)
- Serious concurrent illness or significant cardiac disease characterized by significant ischemic coronary disease or congestive heart failure
- Known human immunodeficiency virus seropositivity, acquired immunodeficiency syndome, hepatitis C or active hepatitis B infection. For Cohort 7, known human herpesvirus-8 seropositivity
- Presence of a transplanted solid organ (with the exception of a corneal transplant more than 3 months prior to screening) or having received an allogeneic bone marrow transplant or an allogeneic peripheral blood stem cell transplant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 (CNTO 328)
Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 2 (CNTO 328)
Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 3 (CNTO 328)
Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 4 (CNTO 328)
Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 5 (CNTO 328)
Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 6 (CNTO 328)
Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 7a (CNTO 328)
Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
Experimental: Cohort 7b (CNTO 328)
Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
|
Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6.
After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a.
Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated.
In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 3 years after the last administration of study medication
|
Number of Patients with adverse events will be reported.
|
Up to 3 years after the last administration of study medication
|
Serum Concentration of CNTO 328
Time Frame: Up to Day 71
|
Serum Concentration of CNTO 328 will be reported.
|
Up to Day 71
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamics of CNTO 328
Time Frame: Up to Day 71
|
Pharmacodynamic parameters C-reactive protein, interleukin-6 (IL-6), soluble IL-6 receptor [GP80], soluble GP130, TNFα, ΙL-8, IL-10, soluble IL-2 receptor (sIL-2R), IFNγ, serum amyloid A (SAA), N-telopeptide (NTx), C-telopeptide (CTx), hepcidin-25, VEGF, and fibroblast growth factor will be assessed.
|
Up to Day 71
|
Plasma antibodies to CNTO 328
Time Frame: Up to Week 24
|
Plasma antibodies to CNTO 328 will be used to evaluate the immunogenicity of CNTO 328.
|
Up to Week 24
|
Number of participants with Castleman's disease who achieved tumor response
Time Frame: Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Evaluation of tumor response for subjects with Castleman's disease were performed by central review according to the standard criteria, developed by an NCI-sponsored international working group (Cheson et al, 1999).
|
Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Number of participants with multiple myeloma who achieved disease response
Time Frame: Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Evaluation of disease response for subjects with Multiple Myeloma were performed by the investigators according to the response criteria developed by an international group of multiple myeloma and bone marrow transplant experts (Blade et al, 1998).
|
Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Number of participants with B-cell non-Hodgkin's lymphoma and multiple myeloma who achieved clinical benefit (CB)
Time Frame: Up to Day 71
|
CB will assess pain (by Pain intensity [PI] and 7-items assessing how much pain interfered with daily activities), performance status (by Karnofsky performance status which quantifies participant's well-being and activities of daily life), and weight change.
PI score will be assessed by 4 questions (Q) rated on 11-point numerical rating scale ranging from "0=no pain" to "10=higher severity of pain".
Each participant will be classified as either CB responder (i.e., if +ve for at least 1 of 3 primary CB measures and stable for other 2) or Non-responder (If a participant is stable on all 3 primary measures OR if -ve for any 1 of 3 primary measures).
|
Up to Day 71
|
Number of participants with Castleman's disease who achieved clinical benefit
Time Frame: Up to Day 71
|
CB assessments for participant with Castleman's disease consist of the following 6 measures: hemoglobin, fatigue, anorexia, fever, weight, and size of largest lymph node.
Each participant will be classified as either improved, stable, or worsening for each of the measures.
If a participant has improved for at least 1 of the 6 measures and is at least stable for the remaining measures, participant will be considered to be a responder for CB.
If a participant has worsening for at least 1 of the 6 measures, participant will be considered as having progression for CB.
Any other participant will be considered to be stable for CB.
Any "improved" or "stable" assessment of the lymph node parameter for CB must be confirmed by radiographic imaging.
If a participant shows progression for CB at 2 consecutive assessments the participant must discontinue study treatment.
|
Up to Day 71
|
Number of participants with B-cell non-Hodgkin's lymphoma who achieved disease response
Time Frame: Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Evaluation of disease response for subjects with B-cell non-Hodgkin's lymphoma were performed by the investigators according to the standard criteria, developed by an NCI-sponsored international working group (Cheson et al, 1999).
|
Screening phase (4 weeks before administration of study medication), Day 36, and Day 57
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
December 15, 2006
First Submitted That Met QC Criteria
December 15, 2006
First Posted (Estimate)
December 18, 2006
Study Record Updates
Last Update Posted (Estimate)
July 1, 2014
Last Update Submitted That Met QC Criteria
June 30, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Lymphoma
- Lymphoma, B-Cell
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Lymphoma, Non-Hodgkin
- Hyperplasia
- Castleman Disease
- Lymphadenopathy
- Antineoplastic Agents
- Siltuximab
Other Study ID Numbers
- CR008566
- C0328T03 (Other Identifier: Centocor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Acerta Pharma BVAstraZenecaActive, not recruitingNon Hodgkin LymphomaUnited States, Canada, Italy
Clinical Trials on CNTO 328
-
Centocor, Inc.CompletedCarcinoma, Renal CellFrance, United Kingdom, Netherlands, Czech Republic
-
Southwest Oncology GroupNational Cancer Institute (NCI)Withdrawn
-
Centocor, Inc.Completed
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)WithdrawnPrimary Myelofibrosis | Polycythemia Vera | Myelofibrosis | Thrombocytopenia
-
Janssen Research & Development, LLCCompletedMulticentric Castleman's DiseaseUnited States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Belgium, Israel, India, Korea, Republic of, Netherlands, Singapore, Brazil, Russian Federation, New Zealand, Hungary, Norway, Australia, Egypt, Hong Kong, Malaysi...
-
Centocor, Inc.CompletedProstatic NeoplasmsUnited States
-
Emory UniversityNational Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...CompletedStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Timothy VoorheesRecruitingNon-Hodgkin LymphomaUnited States
-
Centocor, Inc.CompletedHead and Neck Neoplasms | Lung Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian NeoplasmsUnited States, France, United Kingdom, Spain, Belgium